DESIGN AND CHARECTERIZATION OF NOVEL TRANSDERMAL THERAPEUTIC SYSTEMS OF FELODIPINE by JOSE, JIJI
Jiji Jose et al                                       Journal of Drug Delivery & Therapeutics; 2012, 2(6), 13-20   13 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
Available online at http://jddtonline.info 
RESEARCH ARTICLE 
DESIGN AND CHARECTERIZATION OF NOVEL TRANSDERMAL THERAPEUTIC SYSTEMS OF 
FELODIPINE 
Jiji Jose*
1
, Narayanacharyulu R
2
, Molly Mathew
1
 
1Dept. of Pharmaceutics, Malik Deenar College of Pharmacy, Kasaragod, Kerala-671321, India 
2Dept. of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences, Mangalore, Karnataka-India 
*Corresponding Author’s E-mail: jijimpharm@yahoo.co.in, Mob: +919995987152 
Received 13 Sep 2012; Review Completed 13 Oct 2012; Accepted 17 Oct 2012, Available online 15 Nov 2012 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
In the recent years, considerable attention has been 
focused on the development of new drug delivery 
systems.  The therapeutic efficacy and safety of the drugs 
administered by conventional methods can be improved 
by more precise spatial and temporal placement within 
the body, thereby reducing both the size and number of 
doses through a controlled drug delivery. Among the 
wide variety of novel controlled drug delivery systems, 
the transdermal delivery of drugs for the systemic 
treatment of diseases has acquired increasing interest in 
recent years due to its potential in avoiding the hepatic 
first pass effect, thus achieving high systemic 
bioavailability of drugs and capable of sustaining the drug 
release for prolonged period of time.  Moreover, it 
provides suitability for self-administration and rapid 
termination of drug effect if needed, leading to better 
patient acceptance and compliance1, 2. 
Transdermal therapeutic systems are ideally suited for 
diseases that demand chronic treatment. Cardiac disorders 
such as hypertension, angina pectoris and congestive 
cardiac failure are the diseases equally prevalent in the 
developed and the undeveloped countries, demands 
chronic treatment. Cardiac patients need to be on 
prolonged medication, and some times life long therapy is 
advised. Transdermal delivery is considered to be the 
ideal method for cardiac drugs which can bypass the 
difficulties of firstpass metabolism, enable absolute 
elimination of GIT toxic effects, maintain the steady 
plasma level of drug for a prolonged period and deliver 
the drug at predetermined rate.  Hence, for last two 
decades, it remained an area of vital research of interest 
and industries alike to take up challenging projects in this 
particular arena3. 
Felodipine (FD), a potent calcium channel blocker which 
is widely used in the treatment of hypertension and 
angina pectoris. Although it is rapidly and almost 
completely absorbed from the GIT, it undergoes 
extensive first pass metabolism resulting in a 
bioavailability of about 15% after its oral administration. 
Hence to achieve therapeutic concentration, frequent 
dosing or large doses are required.  Large doses can 
produce bradycardia, hypotension and other adverse 
effects4,5. Hence to improve the bioavailability, 
therapeutic efficacy, patient compliance and to reduce the 
frequency of dosing and its side effects, transdermal drug 
delivery systems are better suitable for FD. 
MATERIALS AND METHODS 
Materials 
Felodipine was obtained as gift sample from Cipla Ltd. 
Mumbai. Eudragit RS 100 (ERS) and Eudragit RL 100 
(ERL) were procured from Degussa India Pvt. Ltd, 
Mumbai. Oleic acid (OA), dibutyl phthalate (DBP), 
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methanol and acetone were of analytical grade purchased 
from Sree Durga Chemicals, Mangalore. Cellophane 
membrane was obtained from Sigma Chemicals Co., St. 
Louis, USA.  
Formulation of transdermal patches
 
The patches were prepared by casting method.  A flat 
square shaped, aluminium foil coated glass molds having 
surface area 25 cm2 were fabricated for casting the 
patches.  
Table 1: Composition of formulations 
 
a. Preparation of Casting Solution 
The casting solutions were prepared by dissolving 
weighed quantities of polymers in acetone-methanol (1:1) 
mixture.  The drug, plasticizer and permeation enhancer 
were then added to the polymer solution and thoroughly 
mixed to form a homogeneous mixture.  The volume was 
made up to 7 ml with solvent mixture.  Entrapped air 
bubbles were removed by applying vacuum.  
Composition of formulation is given in Table 1. 
b. Preparation of Transdermal Patches 
Casting solution (5ml) was poured into glass moulds and 
dried at room temperature for 24 hrs for solvent 
evaporation. The patches were removed by peeling and 
cut into square dims of 4 cm x 4 cm (16 cm2). These 
patches were kept in desiccator for 2 days for further 
drying and wrapped in aluminium foil, packed in self-
sealing covers7-9. 
Physico-mechanical characterization of transdermal 
patches 
a. Physical appearance 
All the formulated transdermal patches were visually 
inspected for colour, flexibility, homogeneity and 
smoothness10. 
b. Thickness
 
The thickness was measured at five different places on a 
single patch using a screw gauge. The average and 
standard deviation of five readings was calculated for 
each batch of the films10-12.   
c. Weight uniformity 
The films of different batches were dried at 60 0C for 4 h 
before testing.  Five patches from each batch having 
diameter of 1cm2 were weighed on a digital balance.  The 
average weight and the standard deviation values were 
calculated from the individual weights12.  
d. Folding endurance 
Folding endurance was measured manually for the 
prepared films. A strip of film (2x 2cm2) was cut evenly 
and repeatedly folded until it broke. The number of times 
the film could be folded at the same place without 
breaking was observed7,13. 
e. Tensile strength 
The tensile strength and percent elongation of the 
prepared films were performed using the method 
developed by Allen et al14. A simple apparatus designed 
at laboratory was used to carry out the measurement 
(Fig.1). A strip of 2.5 x 5 mm was selected and attached 
to a clip on one end of a flat wooden surface. The thread 
was attached carrying a pan at the other end. The points 
of attachments were kept 0.5cm from both the sides, so as 
to get even force distribution and to avoid breaking of 
film abruptly. The other end of thread carrying the pan 
was allowed to slide over a pulley opposite to fixed end. 
Weights were added in the pan in increasing order till the 
point of break-up. The elongation of the film at the point 
of break-up was also measured. The tensile strength was 
calculated as per Alien's formula; Tensile strength = 
(Break force/a x b) X (1+ Δ L/L), where, a is the 
thickness, B is the width of the strip of film, Δ L is the 
elongation at the breaking point and L is the length of the 
test strip (mm). 
Formulation 
Code 
Polymer 
ratio 
ERL/ERS 
ERL  (mg) ERS  
(mg) 
FD (mg) DBP 
(mg) 
OA (mg) Acetone 
up to (ml) 
F1 1:4 140 560 210 - - 7 
F2 2:3 280 420 210 - - 7 
F3 3:2 420 280 210 - - 7 
F4 4:1 560 140 210 - - 7 
F5 4:1 560 140 210 70  7 
F6 4:1 560 140 210 140  7 
F7 4:1 560 140 210 210 - 7 
F8 4:1 560 140 210 140 3.5 7 
F9 4:1 560 140 210 140 7.0 7 
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Figure 1: Instrument for the measurement 
of tensile strength of films 
Figure 2: Instrument for the measurement of hardness 
of films 
f. Hardness 
The apparatus employed for hardness determination was 
designed in the laboratory using the literature report (Fig. 
2).  It consists of a wooden stand of 11 cm height and top 
area of 16 cm × 16 cm.  A small pan was fixed 
horizontally to one end of the 2 mm thick iron rod whose 
other end is reduced to a sharp point.  A hole of 0.2 cm 
was made at the center of top area of a wooden stand, 
which was supporting the pan rod.  An electric circuit was 
made with two 1.5-volt battery and a three volt electric 
bulb in such a way that the bulb lights only when circuit 
is completed through the contact of a metal plate and 
sharp end of the rod.  The film was placed between the 
metal plate and sharp end of the rod.  The increments of 
weights were gradually added at an interval of 10 seconds 
o to the surface of wooden plate and when the hardness of 
the film exceeded, the sharp end penetrates across the 
film, contact the metal plate and the bulb glows. The 
average of five such readings was noted at different 
places of the film and the mean values for the hardness is 
recorded14.  
g. Drug content uniformity  
The film of 1cm2 area was cut into small pieces and 
transferred in to a graduated glass stoppered flask 
containing 15 ml of methanol.  The flask was shaken 
continuously for 24 hrs in a mechanical shaker. Then the 
solution was filtered and residue was washed with 
methanol.  The filtrate was made up to 100 ml with 
phosphate buffer pH 7.4 containing 40% v/v PEG 400 
and the absorbance was measured at 358.5 nm in a double 
beam UV spectrophotometer (Systronics-2203) using the 
placebo film solution as blank and the drug content was 
determined13. 
 In-vitro Drug Release Studies 
In vitro drug release studies were performed by using 
Keshery - Chein diffusion cell with cellophane 
membrane.  The receptor compartment was filled with 30 
ml of phosphate buffer pH 7.4 containing 40% v/v PEG 
400 as diffusion media. The prepared transdermal film of 
1 cm2 was placed in the donor compartment. The whole 
assembly was fixed on a hot plate magnetic stirrer and the 
solution in the receptor compartment was continuously 
stirred at 100rpm using magnetic beads and the 
temperature was maintained at 37 ± 1°C. 3 ml sample of 
the receptor fluid were withdrawn at predetermined time 
intervals and replaced immediately with same volume of 
fresh diffusion media.  The samples were analyzed for 
drug content at 358.5 nm using UV - visible 
spectrophotometer (Systronics-2203) after suitable 
dilution with diffusion media 18. 
Ex-vivo Skin Permeation Studies 
The healthy skin from the forearm region of cadaver 
brought for autopsy was taken in a sealed evacuated 
plastic bag in a thermos containing ice. The human skin 
was freed from fat by the use of Irish scissors till the 
dermis is seen.  The hair was cut and then the skin was 
allowed to stand at room temperature and rehydrated by 
immersing in distilled water for 15 minutes.  Then the 
cadaver skin was mounted between donor and receptor 
compartment of the diffusion cell with epidermis facing 
towards the donor compartment. 30 ml of phosphate 
buffer pH 7.4 containing 1% w/v sodium lauryl sulphate 
was used as elution medium. The films of 1 cm
2
 were 
placed in between the donor and the receptor 
compartment in such a way that the drug releasing surface 
faced toward the receptor compartment. The elution 
medium was magnetically stirred for uniform drug 
distribution at a speed of 100rpm. The temperature of the 
whole assembly was maintained at 37 ± 1°C by 
thermostatic arrangements. An aliquot of 3ml was 
withdrawn at a suitable interval and an equivalent volume 
of fresh buffer was replaced. The amount of drug 
permeated across the membrane was determined at 358.5 
nm spectrophotometrically after proper dilution with the 
elution medium. The cumulative amount of drug 
permeated was calculated and plotted against time18-20. 
Estimation of area of patch required for desired 
release rate 
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The mathematical description of drug release that follow 
zero order kinetics is based on the equation; Kr = 
Ke.Cd.Vd.BW where Kr is rate constant for drug release, 
Ke is the first order rate constant for drug elimination, Cd 
is the therapeutic drug concentration, Vd is the volume of 
distribution and BW is the standard body weight. For 
felodipine, t1/2 = 12 h, Cd = 6.24 µg/ml and Vd = 10 l and 
therefore the desired drug release rate can be calculated as 
Kr = (0.693/12) x 6.24 x 10 x 70 = 252.25 µg/hr. Hence, 
area of patch (A) required for desired release rate is A = 
Kr/ (Kp/S), where Kr is the required drug release rate 
(mg/h) and S is the surface area of the film subjected to 
diffusion (cm2)21,22. 
Compatibility Studies 
The D.S.C. and I.R. studies were performed to check the 
compatibility of drug and polymers. Spectra of the pure 
FD, ERS, ERL and the formulated film (F9) were taken 
individually the peaks were compared for any significant 
deviation. 23,24. 
Stability Study 
The stability studies of the formulated transdermal 
patches were carried out on selected films (F9) as per 
ICH guidelines.  The patches were wrapped in aluminium 
foil and stored at 40 ± 0.50C and 75 ± 5% RH for 3 
months. The sample patches were withdrawn at 0, 30, 60 
and 90 days and analysed for the drug content and drug 
releasing charecteristics24,25.  
Primary Skin Irritancy Studies 
Patches were applied to the shaved skin on one side of the 
back of rabbit and secured using adhesive tape.  On other 
back side of the rabbit, control patch (without drug) was 
secured in a similar way.  The animal was observed for 
any sign of erythema or oedema for a period of 48 hours 
7,16. 
Lamination of Transdermal Patch 
In view of the limited usefulness of the film (Fig. 3) to the 
patient, an attempt has been made to develop the 
complete transdermal therapeutic system of the drug by 
using backing membrane and release liner (Fig. 4). The 
transdermal patch of 1cm diameter was cut and placed on 
an aluminium foil of 1.3 cm diameter that serves as the 
backing membrane. A solution of polyisobutylene was 
applied along the circumference of the aluminium foil 
and dried at room temperature for l0 hrs. The patch was 
covered with silicone coated release liner18. 
. 
 
  
Figure 3: Prepared transdermal film Figure 4: Laminated transdermal patch 
 
RESULTS AND DISCUSSION 
Physico-mechanical characterization 
 In the present study, total nine patches were formulated 
by varying polymer (ERS / ERL) ratio, plasticizer and 
permeation enhancer concentration.  In all these 
formulations a constant amount of drug (210 mg) was 
maintained. 5 ml of the casting solution was spread in to 
25 cm2 so that each cm2 contains approximately 6.0 mg of 
the drug.  The prepared films were slightly pale yellow 
coloured with homogeneous appearance and possessed 
uniform surface. Drug was uniformly distributed through 
the matrix film. There were no observable particles of 
drug in the matrix film. The physicomechanical valuation 
data of the films was presented in Table 2. 
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Table 2: Physico-mechanical characters of formulated transdermal film 
 
The folding endurance was measured manually and it is 
found that ERL / ERS films without adjuvants were hard, 
brittle and fragile with low folding endurance. To prevent 
embrittlement, a plasticizer, DBP was tried at various 
concentrations: 10 %w/w, 20 %w/w and 30%w/w in 
respect to the dry weight of the polymer.   The plasticizer 
can diffuse in to and softens the polymer matrix. Folding 
endurance value were 78 ±1.93 for formulation F1 and 
204 ± 2.07 for formulation F9, other formulations were 
within these ranges, which shown that hydrophilic 
polymer (ERL) and the presence of plasticizer can 
provide higher folding endurance and good flexibility. 
The results suggested that the patches would not break 
and would maintain their integrity with general skin 
folding when applied.  However, the film with 30%w/w 
of DBP was not satisfactory because of its sticky nature.  
The films were evaluated for the film thickness at various 
points. It was found that the thickness at the edges of the 
rectangular tray was a bit higher and uneven compared to 
the rest of the parts of the film. It may be due to the 
curvature of the viscous slurry at the edges of the foil due 
to surface tension. After removing these edges, films 
were remeasured for thickness and it was observed to 
have uniform thickness and low standard deviation. It 
indicates the uniformity of the films prepared by the 
solvent casting method. The thickness was found to be 
high with films prepared with DBP as plasticizer. As the 
proportion of DBP was increased, the thickness was also 
increased (Table 2). No significant difference in the 
average weight among each group indicating that the 
patches are uniform throughout. However the average 
weight of the patches was slightly increased with 
hydrophilic polymer ERL. The increase in the weight 
may be due to the hydrophilic nature of the adjuvants 
which may absorb moisture from the atmosphere 
resulting in increase in weight. It was also found that, 
with the incorporation of hydrophilic polymer, ERL and 
plasticizer, DBP, were increased the tensile strength and 
the percentage elongation where as the hardness of the 
film decreased, but, the incorporation of OA as 
permeation enhancer at 2.5%w/w and 5 %w/w did not 
affect significantly the physicomechanical and handling 
properties of  the film. 
Good uniformity of the drug content among the patches 
was observed for all the formulations which ranged from 
94.75% to 98.42% (Table 3). Based on the initial drug 
loading, all the formulations were containing above 5.628 
± 0.0387 mg, which proves that the process employed to 
prepare the films in this study was capable of producing 
films with uniform drug content and minimum batch 
variability. 
In-vitro drug release studies 
In-vitro drug release studies from transdermal patches 
were carried out through cellophane membrane and the 
results are summarized in Figures 5 and 6. It was 
observed that, as the concentration of ERL increased, the 
percentage of drug release also increased. More 
permeability of these films may be due to its hydrophilic 
nature, which increases the porosity and diffusivity of the 
film and thermodynamic activity of the drug. The release 
pattern of FDP was found to be enhanced significantly 
when DBP was incorporated to the films as plasticizer, It 
is indicated that the drug release rate increased gradually 
as the amount of DBP was increased. The results suggest 
that ERL and DBP had major influence on drug release.   
   
Table 3: Drug content of prepared transdermal films 
 
 
 
 
 
 
 
Formulation 
Code 
Thickness 
(mm) 
Weight (mg) Folding 
Endurance 
% Elongation 
at break 
Tensile strength 
(Kg/cm
2
) 
Hardness 
(Kg) 
F1 0.209 ±0.020 18.647 ±0.154 78 ± 1.93 6.8 ±1.541 0.349 ±0.066 0.438 ±0.047 
F2 0.213 ±0.025 19.232 ±0.208 94  ± 1.51 8.2 ±1.164 0.362 ±0.073 0.423 ±0.032 
F3 0.206 ±0.031 19.784±0.177 112 ± 2.05 8.7 ±1.275 0.375 ±0.051 0.396 ±0.065 
F4 0.214 ±0.022 20.323 ±0.251 119 ± 2.48 9.5 ±1.845 0.389 ±0.012 0.387 ±0.071 
F5 0.226 ±0.012 22.492±0.208 167 ± 1.44 17.4 ±2.075 0.422 ±0.070 0.384 ±0.019 
F6 0.235 ±0.016 23.647 ±0.152 192 ± 2.35 21.5 ±2.204 0.476 ±0.045 0.373 ±0.026 
F7 0.242  ±0.022 24.995 ±0.284 214 ± 3.67 27.1 ±2.516 0.565 ±0.098 0.352 ±0.035 
F8 0.243±0.012 23.931 ±0.173 196 ± 1.92 22.4 ±2.081 0.499 ±0.036 0.376 ±0.029 
F9 0.245 ±0.010 24.267 ±0.157 204 ± 2.07 23.9 ±1.947 0.527 ±0.053 0.375 ±0.057 
Formulation Code 
Amount of drug (1cm
2
) (mg) 
AM ± SD 
Percentage of drug (1cm
2
) 
AM ± SD 
F1 5.716 ± 0.0349 95.278 ± 0.5704 
F2 5.749 ± 0.0343 95.827 ± 0.5679 
F3 5.837 ± 0.0338 97.283 ± 0.5678 
F4 5.734 ± 0.2667 95.556 ± 0.4556 
F5 5.851 ± 0.0515 97.517 ± 0.8585 
F6 5.773 ± 0.0536 96.222 ± 0.9298 
F7 5.640 ± 0.0217 93.955 ± 0.3534 
F8 5.691 ± 0.0381 94.844 ± 0.6609 
F9 5.628 ± 0.0387 93.800 ± 0.6435 
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Figure 5: Effect of polymer composition (ERL/ERS) on  
the in-vitro drug release of formulated transdermal 
films(F1 to F4) 
Figure 6: Effect of the concentration of plasticizer (DBP)  
and permeation enhancer (OA)  on  the in-vitro drug 
release (F4 to F9) 
The rate and mechanism of release of felodipine were 
analysed by fitting the drug release data in to zero order 
equation, first order equation, Higuchi and Korsemayer-
Peppas models. The cumulative amount of drug released 
from the patches, when plotted against square root of 
time, the release profiles of drug seemed to follow 
Higuchi model as it was evidenced by correlation 
coefficients ( r2 = 0.97 to 0.99) better than zero order ( r2 
= 0.95 to 0.97) and first order ( r2 = 0.53 to 0.56) (Fig.7).  
 
 
Figure 7: Higuchi model release of felodipine from transdermal film-F9 
To define the mechanism of drug release from the 
transdermal patches, the data was further analyzed by the 
following empirical equation, Mt/Mα = K tn, where 
Mt/Mα is the fraction of drug released at time t, K is the 
kinetic constant, and n is the diffusional release  exponent 
characterizes the mechanism of drug release. The 
diffusion exponent has a value of 0.587- 0.753, which 
indicated that the drug release was by non-fickian model.  
 
Figure 8: Comparison of in-vitro release and ex-vivo skin permeation of felodipine from transdermal film-F9 
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Ex-vivo drug permeation studies 
The ex-vivo permeation of the drug through human 
cadaver skin was slightly lesser than cellophane 
membrane. However, the incorporation of OA can 
significantly improve the drug permeation characteristics 
through human cadaver skin. (Fig.10). Incorporation of 
OA into the polymer disturbs the continuity of the 
polymer chains, thereby decreasing molecular order and 
increasing the chain mobility of the polymer matrix.  As a 
consequence, permeability enhanced which results in 
increased drug release.  
 
  
Figure 9: Effect of polymer composition (ERL/ERS) 
on  the ex-vivo  skin permeation of  drug from 
transdermal films (F1 to F4)  
Figure 10: Effect of the concentration of plasticizer 
(DBP)  and permeation enhancer (OA)  on  the ex-vivo  
skin permeation of  drug from transdermal film (F4 to F9) 
The in vitro drug release and ex vivo skin permeation 
studies revealed that the combined use of plasticizer and 
permeation enhancers increased the release rate and 
amount of the drug from the patches compared to that of 
their single use.  The incorporation of DBP in to the FD-
eudragit films may be useful for improving the physico-
mechanical and drug release properties of the films and 
the incorporation of OA into the films may be useful for 
attaining required drug permeation.  Thus, the film-F9 
with ERL: ERS ratio 1:4, 2% w/w OA as permeation 
enhancer and 20% w/w DBP as plasticizer showed the 
best results which exhibited the cumulative percentage of 
drug release of 75.73 ± 2.179 % and the cumulative 
amount of drug permeation across skin of 4321 ± 11.533 
µg/cm2 in 24 hrs. The transdermal flux, permeability 
coefficient and area of the film required for desired 
release rate for the transdermal film-F9 were calculated 
and are reported in Table 4. 
Table 4: Transdermal flux, permeability coefficient and 
area of the film required for desired release rate for the 
transdermal film-F9 
Parameters F9 Film 
Cumulative % of drug released-24 hr 75.73 % 
Cumulative amount of drug 
permeated through skin - 24 hr 
4321.2µg/cm2 
Lag time  0.8 hr 
Transdermal flux 187.97 µg/hr/cm2 
Permeability coefficient  3.13 x10-2 cm2/hr 
Targeted  flux  729 µg/hr 
Area of film required for TDDS  3.878 cm2 
Compatibility studies 
The D.S.C. and I. R. studies revealed that there was no 
significant change in the original peak of the drug and the 
polymers after formulating the patch, indicating that there 
is no interaction between drug and polymers. 
Stability study 
Stability studies were carried out for 6 months and the 
films was observed for various physico-mechanical and 
drug release characteristics.  It was found that, there is no 
significant change in physical appearance, thickness, 
weight, folding endurance and tensile strength and drug 
content.  Drug release and permeation characteristics did 
not alter significantly even after 6 months storage. 
Primary skin irritancy studies 
Results of skin irritancy study revealed that neither blank 
patch nor patch containing FD cause any noticeable sign 
of erythema or oedema on rabbit skin throughout the 
period of 48 hrs, indicating the skin compatibility of 
blank patch as well as patch containing drug. 
CONCLUSION 
Based on the physico-mechanical and drug release 
characteristics, ERS 100/RL 100 (1:4) films with DBP 
(20 %w/w) and OA (2 %w/w) are suitable to design 
matrix dispersion type transdermal films for FDP..  The 
fabricated transdermal delivery system containing FDP is 
one of the best controlled drug delivery systems in the 
effective therapy and prophylaxis of hypertension, angina 
pectoris and cardiac arrhythmia, where the drug is made 
available for an extended period of time, so frequency of 
Jiji Jose et al                                       Journal of Drug Delivery & Therapeutics; 2012, 2(6), 13-20   20 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
administration can be minimized. The film composition 
and additives can be optimized to get the release over 
prolonged period of time as once a week or once a month 
transdermal formulations. Further, these findings may 
help the industry to scale up for commercial production. 
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